Soligenix, Inc. (SNGX)
0.44
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 8-K SOLIGENIX, INC. For: May 28
May 28, 2026 5:52 PM - SEC Filing
Form 424B5 SOLIGENIX, INC.
May 28, 2026 5:52 PM - SEC Filing
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
May 26, 2026 7:30 AM - PR NewsWire
Form 424B3 SOLIGENIX, INC.
May 8, 2026 4:17 PM - SEC Filing
Form 424B3 SOLIGENIX, INC.
May 8, 2026 4:14 PM - SEC Filing
Form 424B3 SOLIGENIX, INC.
May 8, 2026 4:13 PM - SEC Filing
Form 424B3 SOLIGENIX, INC.
May 8, 2026 4:12 PM - SEC Filing
Form 10-Q SOLIGENIX, INC. For: Mar 31
May 8, 2026 4:06 PM - SEC Filing
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026 7:30 AM - PR NewsWire
Form 8-K SOLIGENIX, INC. For: Apr 28
April 28, 2026 7:30 AM - SEC Filing
Soligenix halts Phase 3 trial of HyBryte for lymphoma treatment
April 28, 2026 7:30 AM - StreetInsider
Soligenix halts phase 3 trial of HyBryte for lymphoma treatment
April 28, 2026 7:30 AM - StreetInsider
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
April 28, 2026 7:30 AM - PR NewsWire
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
April 10, 2026 10:00 AM - StreetInsider
Form EFFECT SOLIGENIX, INC.
April 3, 2026 6:04 AM - SEC Filing
Form EFFECT SOLIGENIX, INC.
April 3, 2026 6:04 AM - SEC Filing
Form EFFECT SOLIGENIX, INC.
April 3, 2026 6:04 AM - SEC Filing
Form EFFECT SOLIGENIX, INC.
April 3, 2026 6:04 AM - SEC Filing
Soligenix publishes HyBryte study results in Oncology and Therapy
April 2, 2026 7:30 AM - StreetInsider
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
April 2, 2026 7:30 AM - PR NewsWire
Form POS AM SOLIGENIX, INC.
March 31, 2026 4:15 PM - SEC Filing
Form POS AM SOLIGENIX, INC.
March 31, 2026 4:12 PM - SEC Filing
Form POS AM SOLIGENIX, INC.
March 31, 2026 4:11 PM - SEC Filing
Form POS AM SOLIGENIX, INC.
March 31, 2026 4:10 PM - SEC Filing
Form 10-K SOLIGENIX, INC. For: Dec 31
March 31, 2026 4:07 PM - SEC Filing
Soligenix reports $11.1 million net loss for 2025, cash at $7.9 million
March 31, 2026 7:32 AM - StreetInsider
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
March 31, 2026 7:30 AM - PR NewsWire
Soligenix receives EU orphan drug status for Behçet's disease treatment
March 26, 2026 7:31 AM - StreetInsider
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
March 26, 2026 7:30 AM - PR NewsWire
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
March 23, 2026 7:30 AM - PR NewsWire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
March 19, 2026 8:01 AM - Globe NewsWire
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
March 19, 2026 7:30 AM - PR NewsWire
Soligenix receives UK medicine designation for Behcet's disease drug
March 10, 2026 7:30 AM - StreetInsider
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
March 10, 2026 7:30 AM - PR NewsWire
Full Article List
